High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity

Academic Article


  • Gene therapy is proposed as a novel therapeutic strategy for treating glioblastoma multiforme (GBM), a devastating brain cancer. In the clinic, antivector immune responses pose formidable challenges. Herein we demonstrate that high-capacity adenovirus vectors (HC-Ads) carrying the conditional cytotoxic gene herpes simplex virus type 1-thymidine kinase (TK) induce tumor regression and long-term survival in an intracranial glioma model, even in the presence of systemic antiadenovirus immunity, as could be encountered in patients. First-generation Ad-TK failed to elicit tumor regression in this model. These results pave the way for implementing HC-Ad-TK-mediated gene therapy as a powerful adjuvant for treating GBM. Copyright © 2008, American Society for Microbiology. All Rights Reserved.
  • Published In

    Digital Object Identifier (doi)

    Author List

  • King GD; Muhammad AKMG; Xiong W; Kroeger KM; Puntel M; Larocque D; Palmer D; Ng P; Lowenstein PR; Castro MG
  • Start Page

  • 4680
  • End Page

  • 4684
  • Volume

  • 82
  • Issue

  • 9